ReviewBritish journal of cancer2005
Role of survivin and its splice variants in tumorigenesis.
Review in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 224 citations in OpenAlex.
- Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Scientific reports · 2016Pooled it
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.Oncogene · 2024Article
- Targeted splicing therapy: new strategies for colorectal cancer.Frontiers in oncology · 2023Review
- Molecular markers associated with potentially malignant oral lesions (Review).Experimental and therapeutic medicine · 2021Review
- Immunohistochemical evaluation of survivin in oral lichen planus and oral squamous cell carcinoma - a retrospective study.Medicine and pharmacy reports · 2021Article
- Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer.Scientific reports · 2020Article
- Destined to Die: Apoptosis and Pediatric Cancers.Cancers · 2019Review
- Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.Oncotarget · 2018Review
- Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor GrowthClinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Stomatin-like protein 2 regulates survivin expression in non-small cell lung cancer cells through β-catenin signaling pathway.Cell death & disease · 2018Article
- Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.Stem cell investigation · 2017Article
- Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.PloS one · 2017Article
- Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.Cellular & molecular biology letters · 2017Review
- Survivin: a unique target for tumor therapy.Cancer cell international · 2016Review
- Developing Michigan Cancer Foundation 7 Cells with Stable Expression of E7 Gene of Human Papillomavirus Type 16.Iranian journal of pathology · 2016Article
- Evaluation of survivin splice variants in pituitary tumors.Pituitary · 2015Article
- Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.Molecular cancer therapeutics · 2015Article
- Localization and upregulation of survivin in cancer health disparities: a clinical perspective.Biologics : targets & therapy · 2015Review
- Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells.International journal of clinical and experimental pathology · 2015Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Survivin, a unique member of the inhibitor of apoptosis (IAP) protein family, is highly expressed in cancer but is undetectable in nonproliferating normal adult tissues, suggesting a potential role in tumorigenesis. Differential splicing of survivin pre-mRNA results in three new survivin variants, survivin-DeltaEx3, survivin-2B, and survivin-3B. Loss of survivin-2B expression was found in the later stage of cancer development, while survivin and survivin-DeltaEx3 are not, suggesting a differential role of them in tumour development. In this minireview, the author intends to summarise and discuss the current data relevant to the role of survivin and its splicing variants in tumorigenesis, which may facilitate further investigation in this interesting area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.